Sort by

Send to

Choose Destination

Search results

Items: 4


LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients.

Zou X, Chi X, Pan Y, Du D, Sun H, Matsuda A, Li W, Kuno A, Zhang X, Narimatsu H, Niu J, Zhang Y.

Clin Proteomics. 2014 Dec 11;11(1):44. doi: 10.1186/1559-0275-11-44. eCollection 2014.


Comparison of LecT-Hepa and FibroScan for assessment of liver fibrosis in hepatitis B virus infected patients with different ALT levels.

Du D, Zhu X, Kuno A, Matsuda A, Tsuruno C, Yu D, Zhang Y, Ikehara Y, Tanaka Y, Zhang X, Narimatsu H.

Clin Chim Acta. 2012 Nov 12;413(21-22):1796-9. doi: 10.1016/j.cca.2012.07.005. Epub 2012 Jul 13.


LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients.

Ito K, Kuno A, Ikehara Y, Sugiyama M, Saito H, Aoki Y, Matsui T, Imamura M, Korenaga M, Murata K, Masaki N, Tanaka Y, Hige S, Izumi N, Kurosaki M, Nishiguchi S, Sakamoto M, Kage M, Narimatsu H, Mizokami M.

Hepatology. 2012 Oct;56(4):1448-56. doi: 10.1002/hep.25815.


LecT-Hepa: A triplex lectin-antibody sandwich immunoassay for estimating the progression dynamics of liver fibrosis assisted by a bedside clinical chemistry analyzer and an automated pretreatment machine.

Kuno A, Ikehara Y, Tanaka Y, Saito K, Ito K, Tsuruno C, Nagai S, Takahama Y, Mizokami M, Hirabayashi J, Narimatsu H.

Clin Chim Acta. 2011 Sep 18;412(19-20):1767-72. doi: 10.1016/j.cca.2011.05.028. Epub 2011 May 30.


Supplemental Content

Loading ...
Support Center